1-8 Recent European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes state that GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide extended release [ER], dulaglutide, efpeglenatide) should be considered for glucose-lowering treatment in patients with T2D at risk of or with heart failure (HF
Large molecules dont easily cross intestinal walls designed to absorb small nutrients
Lacerations, fractures, contusions, and abrasions are responsible for more than half of all types of toy-related injuries
Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells
Funding This study was not supported by any sponsor or funder
Importantly, preclinical studies have demonstrated that co-administration of GIP and GLP-1 intracerebroventricularly results in an additive enhancement in weight-lowering efficacy (138)